Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: Challenges and opportunities

Clinical Infectious Diseases

Volumn 40, Issue SUPPL. 5, 2005, Pages

  Litwin, Alain H ^a   Soloway, Irene ^a   Gourevitch, Marc N ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHADONE; PEGINTERFERON; RIBAVIRIN;

CHILL; COMORBIDITY; CONFERENCE PAPER; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG DEPENDENCE; HEALTH CARE ACCESS; HEALTH PROGRAM; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION COMPLICATION; INSOMNIA; INTRAVENOUS DRUG ABUSE; IRRITABILITY; LIVER BIOPSY; MEDICAL ASSESSMENT; MEDICAL SERVICE; METHADONE TREATMENT; MYALGIA; NAUSEA; PATIENT CARE; PATIENT COMPLIANCE; PATIENT COUNSELING; PRIORITY JOURNAL; SCREENING TEST; SUBSTANCE ABUSE; WITHDRAWAL SYNDROME;

ADULT; AGED; DELIVERY OF HEALTH CARE, INTEGRATED; ELIGIBILITY DETERMINATION; FEMALE; HEPATITIS C; HUMANS; MALE; METHADONE; MIDDLE AGED; NEW YORK CITY; PILOT PROJECTS; SELF-HELP GROUPS; SUBSTANCE ABUSE, INTRAVENOUS; TREATMENT OUTCOME;

EID: 16844376913     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/427450     Document Type: Conference Paper

References (48)

1. Garfein RS, Vlahov D, Galai N, Doherty MC, Nelson KE. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health 1996; 86:655-61.
2. Murrill CS, Weeks H, Castrucci BC, et al. Age-specific seroprevalence of HIV, hepatitis B virus, and hepatitis C virus infection among injection drug users admitted to drug treatment in 6 US cities. Am J Public Health 2002; 92:385-7.
3. Thomas DL, Vlahov D, Solomon L, et al. Correlates of hepatitis C virus injections among injection drug users. Medicine 1995; 74:212-20.
4. Lorvick J, Kral AH, Seal K, Gee L, Edlin BR. Prevalence and duration of hepatitis C among injection drug users in San Francisco, Calif. Am J Public Health 2001; 91:46-7.
5. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341:556-62.
6. Alter MJ. Epidemiology of hepatitis C. Hepatology 1997; 26:62S-5S.
7. Mann MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358:958-65.
8. Fried MW, Shiffman ML, Reddy R, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-82.
9. Stephenson J. Former addicts face barriers to treatment for HCV. JAMA 2001; 285:1003-5.
10. Edlin BR, Seal KH, Lorvick J, et al. Is it justifiable to withhold treatment for hepatitis C from illicit drug-users? N Engl J Med 2001; 345:211-4.
11. National Institutes of Health. National Institutes of Health Consensus Development Conference statement: management of hepatitis C: 2002. Final statement, 12 September 2002. Available at http://consensus.nih.gov/cons/116/ 091202116cdc_statement.htm [accessed 2 October 2004].
12. Mauss S, Berger F, Goelz J, Jacob B, Schmutz G. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology 2004; 40:120-4.
13. Laine C, Hauck WW, Gourevitch MN, Rothman J, Cohen A, Turner BJ. Regular outpatient medical and drug abuse care and subsequent hospitalizations of persons who use illicit drugs. JAMA 2001; 285:2355-62.
14. Weisner C, Mertens J, Parthasarathy S, Moore C, Lu Y. Integrating primary medical care with addiction treatment: a randomized controlled trial. JAMA 2001; 286:1715-23.
15. Selwyn PA, Feingold AR, Iezza A, et al. Primary care for patients with human immunodeficiency virus (HIV) infection in a methadone maintenance treatment program. Ann Intern Med 1989; 111:761-3.
16. Novick DM. The impact of hepatitis C virus infection on methadone maintenance treatment. Mt Sinai J Med 2000; 67:437-43.
17. O'Connor PG, Molde S, Henry S, Shockcor WT, Schottenfield RS. Human immunodeficiency virus infection in intravenous drug users: a model for primary care. Am J Med 1992; 93:382-6.
18. Gourevitch MN, Wasserman W, Panero MS, Selwyn PA. Successful adherence to observed prophylaxis and treatment of tuberculosis among drug users in a methadone program. J Addict Dis 1996; 15:93-104.
19. Selwyn PA, Budner NS, Wasserman WC, Arno PS. Utilization of on-site primary care services by HIV-seropositive and seronegative drug users in a methadone maintenance treatment program. Public Health Rep 1993; 108:492-500.
20. Umbricht-Schneiter A, Ginn DH, Pabst KM, Bigelow GE. Providing medical care to methadone clinic patients: referral vs. on-site care. Am J Public Health 1994; 84:207-10.
21. Selwyn PA, Alcabes P, Hartel D, et al. Clinical manifestations and predictors of disease progression in drug users with human immunodeficiency virus infection. N Engl J Med 1992; 327:1697-703.
22. Gourevitch MN, Hartel D, Selwyn PA, Schoenbaum EE, Klein RS. Effectiveness of isoniazid chemoprophylaxis for HIV-infected drug users at high risk for active tuberculosis. AIDS 1999; 13:2069-74.
23. Best D, Noble A, Finch E, Gossop M, Sidwell C, Strang J. Accuracy of perceptions of hepatitis B and C status: cross-sectional investigation of opiate addicts in treatment. BMJ 1999; 319:290-1.
24. Strasfeld L, Lo Y, Netski D, Thomas DL, Klein RS. The association of hepatitis C prevalence, activity, and genotype with HIV infection in a cohort of New York City drug users. J Acquir Immune Defic Syndr 2003; 33:356-64.
25. Rounsaville BJ, Weissman MM, Crits-Christoph K, Wilber C, Kleber H. Diagnosis and symptoms of depression in opiate addicts. Course and relationship to treatment outcome. Arch Gen Psychiatry 1982; 39:151-6.
26. Schmitz JM, Stotts AL, Averill PM, et al. Cocaine dependence with and without comorbid depression: a comparison of patient characteristics. Drug Alcohol Depend 2000; 60:189-98.
27. Turrina C, Fiorazzo A, Turano A, et al. Depressive disorders and personality variables in HIV positive and negative intravenous drug-users. J Affect Disord 2001; 65:45-53.
28. Johnson ME, Fisher DG, Fenaughty A, Theno SA. Hepatitis C virus and depression in drug users. Am J Gastroenterol 1998; 93:785-9.
29. Zdilar D, Franco-Bronson K, Buchler N, Locala JA, Younossi ZM. Hepatitis C, interferon alfa, and depression. Hepatology 2000; 31:1207-11.
30. Djavaherian C, Clements B, Sylvestre DL. Treating hepatitis C in recovering injection drug users (IDUs) with psychiatric disease [abstract 8A]. J Addict Dis 2002; 21:112.
31. Sylvestre DL. Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug Alcohol Depend 2002; 67:117-23.
32. Backmund M, Meyer K, Von Zielonka M, Eichenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology 2001; 34:188-93.
33. Sullivan LE, Fiellin DA. Hepatitis C and HIV infections: implications for clinical care in injection drug users. Am J Addict 2004; 13:1-20.
34. Dalgard O, Bjoro K, Hellum K, et al. Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up. Eur Addict Res 2002; 8:45-9.
35. Nikitin IG, Kuznetsov SL, Liuliaeva OD, Storozhakov GI, Kisliakov VA, Uskov IUI. Therapeutic response to alpha-interferon in chronic alcoholics with viral hepatitis C. Klinicheskaia Meditsina 1998; 76:33-5.
36. McCusker M. Influence of hepatitis C status on alcohol consumption in opiate users in treatment. Addiction 2001; 96:1007-14.
37. Graney MJ, Bunting SM, Russell CK. HIV/AIDS medication adherence factors: inner-city clinic patients' self-reports. Tenn Med 2003; 96:73-8.
38. Stone VE, Clarke J, Lovell J, et al. HIV/AIDS patients' perspectives on adhering to regimens containing protease inhibitors. J Gen Intern Med 1998; 13:586-93.
39. Puigventos F, Riera M, Delibes C, Penaranda M, de la Fuente L, Boronat A. Adherence to antiretroviral drug therapy: a systematic review [in Spanish]. Med Clin (Barc) 2002; 119:130-7.
40. National Institutes of Health (NIH). Management of hepatitis C: NIH Consensus Development Conference Statement, 24-26 March 1997. Available at: http://consensus.nih.gov/cons/105/105_statement.htm [accessed 2 October 2004].
41. Kreek MJ, Garfield JW, Gutjahr CL, Giusti LM. Rifampin-induced methadone withdrawal. N Engl J Med 1976; 294:1104-6.
42. Cobb M, Desai J, Brown LS Jr, Zannikos PN, Rainey PM. The effects of fluconazole on the clinical pharmacokinetics of methadone. Clin Pharmacol Ther 1998; 63:655-62.
43. Clarke SM. The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. Br J Clin Pharmacol 2001;51:213-7.
44. Altice FL. Nevirapine induced opioid withdrawal among injection drug users with HIV infection receiving methadone. AIDS 1999; 13:957-62.
45. Sulkowski MS. Pharmacokinetics, pharmacodynamics, and antiviral response in patients with chronic hepatitis C infection on methadone maintenance therapy receiving peginterferon alfa-2a [abstract 231]. In: Program and abstracts of Digestive Disease Week (Orlando, FL). San Francisco: HIV and Hepatitis.com, 2003. Available at: http://www.hivandhepatitis.com/2003icr/DDW2003/main.html [accessed 2 October 2004].
46. McCance-Katz EF, Gourevitch MN, Arnsten J, Sarlo J, Rainey P, Jatlow P. Modified directly observed therapy (MODT) for injection drug users with HIV disease. Am J Addict 2002; 11:271-8.
47. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype 1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123:1061-9.
48. Hauser P, Khosla J, Aurora H, et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry 2002; 7:942-7.